BridgeBio Pharma (BBIO) total debt

Total debt · fiscal 2025
$1.86B

BridgeBio Pharma (BBIO) carried total debt of $1.86B at the end of fiscal 2025 (December 31, 2025). That is 7.6% higher than the $1.73B of fiscal 2024. Figures as of 18 Nov 2026, 09:37 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total debt, fiscal 2025
$1.86B
Change on fiscal 2024
+7.6%
Growth, 5 years
+81.8% a year
Highest on record
$1.86Bfiscal 2025
Lowest on record
$54.51Mfiscal 2018
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

BridgeBio Pharma total debt, in more detail

Over the five fiscal years to 2025 total debt grew at a compound 81.8% a year. Across the 8 fiscal years on record (2018–2025), the highest was $1.86B in fiscal 2025 and the lowest $54.51M in fiscal 2018.

History · 8 fiscal years

Total debt by fiscal year

BridgeBio Pharma total debt, year by year

BridgeBio Pharma (BBIO) total debt by fiscal year
Fiscal yearTotal debtChangeYear endedDebt ÷ equity
2025$1.86B 7.6% up—
2024$1.73B 0.5% down—
2023$1.74B 0.9% up—
2022$1.72B 300.1% up—
2021$430.75M 358.8% up—
2020$93.88M 1.6% down1.6×
2019$95.37M 75.0% up0.2×
2018$54.51M—0.2×

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

How to read it

Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.

Total debt at health care companies of similar size

Total debt of BridgeBio Pharma and comparable companies
CompanyTotal debtFiscal year
ICON ICLR$3.56B2025
Jazz Pharmaceuticals JAZZ$5.42B2025
Solventum SOLV$5.04B2025
BridgeBio Pharma BBIO$1.86B2025
Summit Therapeutics SMMT$20.89M2025
Glaukos GKOS$103.88M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BBIO

BridgeBio Pharma, figure by figure

BridgeBio Pharma (BBIO) overview: price, valuation and scorecardAll health care companies by market value

BridgeBio Pharma total debt: questions and answers

How much debt does BridgeBio Pharma have?

BridgeBio Pharma (BBIO) carried total debt of $1.86B at the end of fiscal 2025 (December 31, 2025). That is 7.6% higher than the $1.73B of fiscal 2024.

What is the growth rate of BridgeBio Pharma's total debt?

Over the five fiscal years to 2025 total debt grew at a compound 81.8% a year.

What are the highest and lowest total debt figures on record for BridgeBio Pharma?

Across the 8 fiscal years on record (2018–2025), the highest was $1.86B in fiscal 2025 and the lowest $54.51M in fiscal 2018.

How is BridgeBio Pharma's total debt calculated?

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative. For BridgeBio Pharma it is on record here for 8 fiscal years, 2018 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BridgeBio Pharma (BBIO) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/BBIO/total-debt

Underlying data: the company's filings with the SEC and Yahoo Finance.